A @SAGE_Publishing gold OA journal | Publishing innovative clinically focused articles on the medical treatment of cancer| IF: 4.1| Editor @LinglingTian123
London, UK
Joined January 2018
- Tweets1.1K
- Following1.3K
- Followers720
- Likes1.2K
Pinned Tweet
We're now on Bluesky! 🌟 Follow us for the latest in oncology research, expert insights, and journal updates—now across platforms.
🔗 Join us on Bluesky: bsky.app/profile/tamedoncol.…
#Oncology #CancerResearch #MedicalScience
The debate on the optimal duration of #immunotherapy in advanced #NSCLC remains open: 2 years or indefinitely?
This systematic review and network meta-analysis recently published in #TAMO may help answer this question.
Have a look here 👇️
buff.ly/qvptCEx
How common are gastrointestinal adverse events after #TACE in pts with #HCC?
In 2025, we published this meta-analysis in #TAMO (81 studies and 9495 pts) showing that abdominal pain, nausea, and diarrhea were the most frequent AEs!
buff.ly/weSh4qW
T-cell engagers in solid tumors and #neurotoxicity?
Have a look to this new systematic #review in #TAMO: 36 studies, 2.743 patients. ICANS occurred in 6.3%, mainly with #DLL3-targeting agents; severe events were uncommon.
buff.ly/HF05H6u
@MarianaBrandao0 @sandrineaspesla
Get ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025.
From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers.
#Lungcancer
🔗 buff.ly/B2U9VpQ
@Roya_Behrouzi @fblackhall
Online on #TAMO
Lymphocyte recovery after breast RT may take years.
In 203 pts from the phase III CHN HYPOBREAST trial, HFRT was associated with less ≥G2 lymphopenia vs CFRT (6.5% vs 24.5%) and earlier recovery to baseline.
#BreastCancer #RadOnc
buff.ly/gW1OmN9
On #TAMO in 2025
How can AR-targeted therapy move beyond resistance in #prostate cancer?
Emerging strategies (i.e. CYP11A1 inhibition/AR degraders/EZH2 inhibitors) are explored in this comprehensive review.
@alicebernardt
buff.ly/fzcWHPk
🩸 How can a lipid–endothelial #signature stratify patients with #HCC?
Luxi Yang et al. explore this through an integrated multi-omics approach, linking a six-gene signature with prognosis and immune-excluded features in HCC.
🔗 buff.ly/YnGZpEo
On #TAMO in 2025
🤰 Fertility preservation is a key component of care for young patients with #breast #cancer.
Interesting evidence in this RW cohort where 54% underwent cryopreservation.
More details here: buff.ly/SyJrDPh @matteolambe
Evidence in NUT #carcinoma remains limited. This retrospective series of 25 H&N offers interesting insights into histologic differentiation and prognosis, including the adverse prognostic association of neuroendocrine differentiation.
buff.ly/Evhy0A9
On #TAMO in 2025.
.
End-of-life care is crucial in pancreatic #cancer. In this French cohort, 41% of pts received high-intensity EOL care, while #palliativecare involvement was associated with lower care intensity.
.
👉 buff.ly/PyI4jy2
Management of #testicular #cancer still diverges from guidelines.
Adj treatment remains common in stage I disease despite surveillance-based recommendations, while repeat imaging in stage IIA is inconsistently used.
More details 👉️ buff.ly/3oeKQLu
#oncology #realworld
On #TAMO in 2025
💊 🫁 🧬
Real-world evidence on selpercatinib in RET-rearranged #NSCLC is limited. In this updated analysis of LIBRETTO-321, selpercatinib showed durable responses, prolonged survival, and a good safety profile in Chinese patients.
buff.ly/sJC7QFL
Are T-cell engagers ready to reshape the #treatment of solid #tumors?
This review summarizes current evidence on their safety profile and AE management, key challenges in clinical practice.
buff.ly/PX0OyXa
@nicogirardcurie #TAMO #oncology
On #TAMO in 2025.
.
In a retrospective 20-center study, a depth of response ≥15% independently predicted longer PFS in pre-treated BRAFV600E #mCRC receiving encorafenib + cetuximab ± binimetinib.
Read more:
buff.ly/LjtvYEA
@Guv_onc @ChiaraCrem1 #colorectal #cancer
How are new treatment options reshaping #ovarian #cancer care?
In this review, @anacveneziani et al. focus on platinum-resistant disease and the emerging therapeutic strategies expanding treatment options for these patients.
.
buff.ly/CinYlnU
#oncology #research #TAMO
On #TAMO in #2025
.
What is the impact of treatment-related deaths (TRDs) in #HNC pts treated with #CRT?
A meta-analysis led by Gurizzani reported a 1.4% rate of TRDs, highlighting the need for careful pts selection and more intensive supportive care.
buff.ly/IWinh1Z
Online on #TAMO
👇🏽
With 1695 pts from 58 centers the Meet-URO 33–REGAL study shows an interesting real-world snapshot of #1L decision-making in #mRCC.
buff.ly/qKZSbw5
.
@gbanna74 @rebuzzisara @meeturoIT
#Nectin-4 is a key target for #ADCs in #urothelial carcinoma. This study evaluated Nectin-4 features in bladder #UC and #UTUC, revealing distinct expression patterns and associated immune contextures.
buff.ly/vFzQdrH
Therapeutic Advances in Medical Oncology retweeted
🚨 New consensus paper in @TAMedOncol: an international steering committee issues 55 recommendations for preventing & managing Dato-DXd (datopotamab deruxtecan) side effects in advanced/metastatic #NSCLC — oral mucositis, ILD/pneumonitis, ocular surface events, nausea & vomiting.
Key message: early detection, proactive patient communication & multidisciplinary care are essential to protect patients' quality of life.
Grateful to have contributed alongside @stephanieplsaw and colleagues from centres across #HongKong, #Brazil, #Australia, #Egypt, #India, #Singapore, #SouthKorea, #Taiwan & #Turkey.
📖 Read it (open access): doi.org/10.1177/175883592614…
#LungCancer #ADC #TROP2 #drugdevelopment @CUHKMedicine
